Clinical Trial Update: V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on V501 in Japanese women (16-26) assessing safety and efficacy; completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma in Situ
• Cervical Cancer
• Cervical Intraepithelial Neoplasia

Drugs mentioned

• V501 (HPV vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasia | Phase 4 | Status: COMPLETED | Results posted: 2017-07-07